Novozymes A/S B (0Q4U)
London Stock Exchange · UK · prices in DKK · close of 27 Oct 2026
Key indicators
| Last close | DKK 470.35 |
|---|---|
| 52-week range | 337.50 – 478.40 |
| Return, 1 month / 3 months | +10.2% / +16.0% |
| Return, 1 year / 3 years | +20.8% / +58.4% |
| Trend | Uptrend |
| RSI (14) | 66 |
| Volatility (1 year) | 26.1% |
| Worst drawdown (1 year) | -20.1% |
| Average daily value traded | 93.53M DKK |
| Dividend yield | 1.4% |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Novozymes is a Danish industrial biotechnology company that makes enzymes and microorganisms used in manufacturing and agriculture. Its products help customers in household care, food and beverages, bioenergy, and farming improve their processes. The company is based in Denmark and supplies industrial customers around the world. Its work centres on biological solutions that replace or complement traditional chemical processes in a range of industries.
The shares are listed on the London Stock Exchange in UK under the code 0Q4U, and the price on this page is in Danish kroner (DKK). Our dividend records, which start in 2019, show payments in 8 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Novozymes A/S B (0Q4U) trades on the London Stock Exchange in UK. It last closed at DKK 470.35 on 27 October 2026.
Its price-based Market X-Ray is 75 out of 100 (a strong price profile), ranking 257 of 3,788 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price rose 20.8% and over the last three months it rose 16.0%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on London Stock Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 85 · Strong | Trading above its long-term averages and near its highs. | |
| Above 200-day average | 17.3% | ||
| From 52-week high | -1.7% | ||
| Momentum | 76 · Strong | Rising faster than most stocks on this exchange. | |
| 3-month return | 16.0% | ||
| 6-month return | 23.6% | ||
| 12-month return, skipping the last month | 9.6% | ||
| Stability (higher is calmer) | 73 · Strong | Calmer than most: low volatility and shallow drawdowns. | |
| Volatility, 1 year (lower is calmer) | 26.1% | ||
| Worst drawdown, 1 year (smaller is calmer) | -20.1% | ||
| Liquidity | 89 · Strong | Trades actively. | |
| Average daily value traded | 93.53M DKK | ||
| Zero-volume days | 0.0% | ||
| Income | 32 · Weak | Dividend is small or irregular. | |
| Dividend yield | 1.4% | ||
| Years with dividends | 5 |
Strengths
- Trend: Trading above its long-term averages and near its highs.
- Momentum: Rising faster than most stocks on this exchange.
- Stability (higher is calmer): Calmer than most: low volatility and shallow drawdowns.
- Liquidity: Trades actively.
Weak spots
- Income: Dividend is small or irregular.
Returns
| 1 week | +1.8% |
|---|---|
| 1 month | +10.2% |
| 3 months | +16.0% |
| 6 months | +23.6% |
| 1 year | +20.8% |
| 3 years | +58.4% |
| 5 years | +9.4% |
Signals
| 50-day / 200-day average | 441.29 / 400.97 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | Yes |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 7.17 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 25 Aug 2026 | DKK 2.3500 |
| 24 Mar 2026 | DKK 4.2500 |
| 21 Aug 2025 | DKK 2.2500 |
| 4 Apr 2025 | DKK 4.2000 |
| 30 Aug 2024 | DKK 2.0000 |
| 1 May 2024 | DKK 2.0000 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on London Stock Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.